Send this resource to your team or professional network.
Comparing NAD oral supplementation to injectable delivery reveals critical bioavailability differences — the 2023 NAD+ bioavailability review (Nutrients) and NMN pharmacokinetics data establish why researchers compare NAD oral vs injectable for acute NAD+ repletion protocols.
NAD Oral vs Injectable: Bioavailability and Evidence Comparison
NAD+ (nicotinamide adenine dinucleotide) cannot be effectively delivered as an intact oral supplement — the molecule is too large and too polar to cross intestinal epithelium efficiently at meaningful doses. Research on NAD+ delivery has therefore taken two directions: injectable NAD+ that bypasses the gut entirely, and oral precursors (NMN, nicotinamide riboside) that the body converts to NAD+ after absorption. This article compares the evidence for each route and explains where NMN fits in the picture.
Why NAD+ Bioavailability Is the Core Problem
NAD+ declines with age. The decline is well-documented: blood NAD+ levels in 60-year-olds are roughly 50% of those in 20-year-olds, with similar declines measured in skeletal muscle and liver biopsies.[1] NAD+ supports mitochondrial function (Complex I of the electron transport chain), DNA repair via PARP enzymes, and sirtuin (SIRT1–7) deacylase activity — the same sirtuins targeted by caloric restriction research.
Supplementing NAD+ itself orally is inefficient because extracellular NAD+ is cleaved by CD38 and ENPP1 ectoenzymes on cell surfaces before it can enter cells. The products of that cleavage — nicotinamide (Nam) and ADP-ribose — can be recycled back to NAD+ through the salvage pathway, but this is indirect and inefficient at scale. The current evidence favors delivering precursors that enter cells via dedicated transporters and are converted to NAD+ intracellularly.
Injectable NAD+: What the Evidence Shows
Intravenous (IV) or subcutaneous NAD+ bypasses gut absorption entirely. IV NAD+ administration is used in clinical settings primarily in the context of addiction medicine — a 2023 randomized pilot trial (Grant et al., N=22) found that IV NAD+ over 4 days reduced alcohol withdrawal severity scores and opioid craving compared to saline placebo, with no serious adverse events.[2]
For age-related NAD+ decline specifically, the injectable route produces rapid NAD+ elevation measurable in blood within hours. The limitation is that blood NAD+ elevation does not necessarily translate proportionally to tissue NAD+ elevation — different tissues have different NAD+ pools and different rates of NAD+ turnover. A 2018 metabolic flux study by Liu et al. found that the liver has the highest NAD+ synthesis rate (primarily via the de novo tryptophan–quinolinic acid pathway), while muscle relies more heavily on the salvage pathway — meaning the route of precursor delivery matters differently for each tissue target.[3]
Subcutaneous NAD+ injection is used in research settings as an alternative to IV. The pharmacokinetics differ (slower peak, potentially longer absorption window) but this has not been well-characterized in published literature. The IV route has a broader evidence base; subcutaneous is inferred from general peptide/small-molecule pharmacokinetic principles.
Oral NAD+ Precursors: NMN and Nicotinamide Riboside
The oral route to raising NAD+ works by delivering precursors that are taken up by intestinal cells and converted to NAD+ via the salvage pathway:
Nicotinamide Riboside (NR)
NR is a form of vitamin B3 that enters cells via dedicated NR transporters (SLC12A8) and equilibrative nucleoside transporters. A double-blind crossover trial in healthy middle-aged and older adults (Trammell et al., 2016, N=12) showed that oral NR supplementation at 1,000 mg/day significantly increased whole-blood NAD+ levels (average increase ~2.7-fold) vs. placebo over 7 days, with a dose-dependent response.[4]
A subsequent trial by Martens et al. (2018, N=24) supplemented older adults with NR (500 mg twice daily) for 6 weeks. Blood NAD+ metabolomics showed significant increases in NAD+ and downstream metabolites. The study also found no increase in inflammatory markers and good tolerability throughout.[5]
NMN (Nicotinamide Mononucleotide)
NMN is one step upstream of NAD+ in the salvage pathway. For years it was debated whether NMN could enter cells directly or required conversion to NR first. A 2019 study by Grozio et al. identified SLC12A8 as a dedicated NMN transporter in the mouse small intestine — suggesting NMN can be taken up directly without first being converted to NR.[6] This was a significant mechanistic finding, though later research has debated whether SLC12A8 transports NMN efficiently in humans.
A human trial by Igarashi et al. (2022, N=25) found that oral NMN supplementation at 250 mg/day for 12 weeks significantly increased NAD+ levels in blood and improved physical function metrics in older adults, with no serious adverse events.[7]
NMN vs NAD+: What Actually Differs
This is the most common comparison question. The distinction:
| NAD+ (direct) | NMN | NR (Nicotinamide Riboside) | |
|---|---|---|---|
| Molecular size | 663 Da (large) | 334 Da (medium) | 255 Da (small) |
| Oral bioavailability | Poor (degraded extracellularly) | Good (direct transporter, some conversion to NR) | Good (well-characterized uptake) |
| Injectable form | Yes — used IV/SC | Not commonly used | Not commonly used |
| Steps to NAD+ | 0 (direct; if it can enter cell) | 1 (NMN → NAD+ via NMNAT) | 2 (NR → NMN → NAD+) |
| Human RCT data | Limited (mostly addiction/withdrawal context) | Growing (Igarashi 2022 and others) | Best established (Trammell 2016, Martens 2018) |
No head-to-head RCT has compared equivalent doses of injectable NAD+ vs oral NMN vs oral NR for blood or tissue NAD+ elevation in the same population. Comparing these routes from separate trials is confounded by different doses, populations, and measurement methods.
Nicotinamide Riboside vs NMN: Which Oral Precursor?
Both NR and NMN have human evidence for raising blood NAD+ when taken orally. The differences:
- NR has a longer track record in human trials and more published safety data over sustained supplementation periods. It converts to NMN and then NAD+ via a two-step process.
- NMN is one step closer to NAD+ and has a dedicated intestinal transporter (SLC12A8 in mice; debated in humans). Higher-dose human trial data is accumulating.
- Price: NMN is typically more expensive per gram than NR at comparable doses.
- Both are generally well-tolerated. Neither has a known serious adverse event profile at typical supplementation doses (250–500 mg/day range).
The practical difference for most research contexts is small. NR has the larger published human trial database; NMN has theoretical mechanistic advantages (one step closer to NAD+, possible direct cellular uptake) that may or may not translate to meaningfully different outcomes.
NAD+ Research in Canada
Injectable NAD+ and oral NAD+ precursors (NMN) are available as research chemicals in Canada from suppliers including Anglo Peptides. Research-grade NAD+ should be confirmed for identity and purity by HPLC and mass spectrometry; a certificate of analysis with batch-specific data is the standard quality document to request before purchase.
NAD+ is sensitive to heat, light, and moisture — lyophilized powder should be stored away from UV light and at cool temperatures. Reconstitute immediately before use and do not store reconstituted solutions for extended periods without preservative.
Frequently Asked Questions
Is NAD+ injectable better than oral?
Injectable NAD+ bypasses the gut absorption limitation and produces rapid blood NAD+ elevation. However, no head-to-head trial has compared injectable NAD+ to oral NMN or NR directly for aging-related outcomes. Injectable NAD+ has the most evidence in addiction/withdrawal contexts; oral NMN and NR have more evidence in healthy-aging and metabolic research. The “better” route depends on the specific research question.
Is NMN the same as NAD+?
No. NMN (nicotinamide mononucleotide) is a precursor to NAD+, not NAD+ itself. NMN is one biosynthetic step upstream — it is converted to NAD+ by NMNAT enzymes inside cells. NMN is 334 Da; NAD+ is 663 Da. Oral NMN raises NAD+ indirectly via this conversion; oral NAD+ itself is poorly absorbed intact.What is the NMN vs NAD+ difference for supplementation?
For oral supplementation, NMN is more practical because it is absorbed more effectively than intact NAD+. For injectable use, NAD+ is used directly because injection bypasses the absorption barrier. NMN injections exist but are not commonly used in published research; injectable NAD+ has more clinical data.
What does NAD+ injection do?
IV or subcutaneous NAD+ injection rapidly raises blood NAD+ levels, bypassing the intestinal absorption barrier. Clinical applications with published data include alcohol withdrawal and opioid craving reduction (Grant et al., 2023). Anti-aging and metabolic applications are being researched but large randomized trial evidence is limited as of 2026.References
- Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127–1139. PMID 27304508
- Grant JE, et al. A pilot study of intravenous nicotinamide adenine dinucleotide for alcohol use disorder. Am J Addict. 2023;32(4):363–370. PMID 37179398
- Liu L, et al. Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metab. 2018;27(5):1067–1080. PMID 30415997
- Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in healthy humans. Nat Commun. 2016;7:12948. PMID 27721479
- Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. PMID 29514871
- Grozio A, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(1):47–57. PMID 30778595
- Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022;8(1):5. PMID 34466232
Related Research Articles
Explore related peptide research: Tesamorelin Canada Guide, BPC-157 Arginate vs Acetate, and GLP-1 Receptor Agonist Complete Guide.
